Atara Biotherapeutics (ATRA) Work In Process (2022 - 2024)

Atara Biotherapeutics (ATRA) has reported Work In Process for 3 consecutive years, with $9.7 million the latest figure, recorded in Q4 2024.

• For the quarter ending Q4 2024, Work In Process rose 31.47% year-over-year to $9.7 million; the trailing twelve-month figure through Dec 2024 stood at $9.7 million (up 31.47% YoY), and the FY2024 full-year result was $9.7 million, up 31.47% from the prior year.
• Work In Process declined to $9.7 million in Q4 2024 per ATRA's latest filing, from $12.3 million in the prior quarter.
• Across five years, Work In Process topped out at $15.1 million in Q2 2024 and bottomed at $372000.0 in Q4 2022.
• Historically, Work In Process has averaged $7.8 million across 3 years, with a median of $7.4 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Work In Process soared 1881.45% in 2023, then surged 31.47% in 2024.
• Over 3 years, Work In Process stood at $372000.0 in 2022, then jumped by 1881.45% to $7.4 million in 2023, then soared by 31.47% to $9.7 million in 2024.
• According to Business Quant data, Work In Process over the past three periods registered $9.7 million, $12.3 million, and $15.1 million for Q4 2024, Q3 2024, and Q2 2024 respectively.